Jan Gunnar Hatlebakk

List of Publications by Year
in descending order

47	1,418	331670 21	345221 36
papers	citations	h-index	g-index

48	48	48	1197
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut, 2020, 69, 859-867.	12.1	291
2	Diet in Irritable Bowel Syndrome (IBS): Interaction with Gut Microbiota and Gut Hormones. Nutrients, 2019, 11, 1824.	4.1	86
3	Is irritable bowel syndrome an organic disorder?. World Journal of Gastroenterology, 2014, 20, 384.	3.3	79
4	Pharmacokinetic Optimisation in the Treatment of Gastro-Oesophageal Reflux Disease. Clinical Pharmacokinetics, 1996, 31, 386-406.	3.5	71
5	The kinetics of gut microbial community composition in patients with irritable bowel syndrome following fecal microbiota transplantation. PLoS ONE, 2018, 13, e0194904.	2.5	59
6	Irritable bowel syndrome the role of gut neuroendocrine peptides. Frontiers in Bioscience - Elite, 2012, E4, 2683-2700.	1.8	55
7	The relation between celiac disease, nonceliac gluten sensitivity and irritable bowel syndrome. Nutrition Journal, 2015, 14, 92.	3.4	53
8	The role of peptide YY in gastrointestinal diseases and disorders. International Journal of Molecular Medicine, 2013, 31, 275-282.	4.0	50
9	Increasing the Dose and/or Repeating Faecal Microbiota Transplantation (FMT) Increases the Response in Patients with Irritable Bowel Syndrome (IBS). Nutrients, 2019, 11, 1415.	4.1	39
10	Changes in fecal shortâ€chain fatty acids following fecal microbiota transplantation in patients with irritable bowel syndrome. Neurogastroenterology and Motility, 2021, 33, e13983.	3.0	37
11	Irritable bowel syndrome: recent developments in diagnosis, pathophysiology, and treatment. Expert Review of Gastroenterology and Hepatology, 2014, 8, 435-443.	3.0	36
12	Endocrine cells in the ileum of patients with irritable bowel syndrome. World Journal of Gastroenterology, 2014, 20, 2383.	3.3	35
13	Efficacy of Fecal Microbiota Transplantation for Patients With Irritable Bowel Syndrome at 3 Years After Transplantation. Gastroenterology, 2022, 163, 982-994.e14.	1.3	35
14	Possible role of peptide YY (PYY) in the pathophysiology of irritable bowel syndrome (IBS). Neuropeptides, 2020, 79, 101973.	2.2	30
15	Clinical response to fecal microbiota transplantation in patients with diarrhea-predominant irritable bowel syndrome is associated with normalization of fecal microbiota composition and short-chain fatty acid levels. Scandinavian Journal of Gastroenterology, 2019, 54, 690-699.	1.5	29
16	Current status of fecal microbiota transplantation for irritable bowel syndrome. Neurogastroenterology and Motility, 2021, 33, e14157.	3.0	29
17	Duodenal Chromogranin A Cell Density as a Biomarker for the Diagnosis of Irritable Bowel Syndrome. Gastroenterology Research and Practice, 2014, 2014, 1-8.	1.5	28
18	Effect of a cod protein hydrolysate on postprandial glucose metabolism in healthy subjects: a double-blind cross-over trial. Journal of Nutritional Science, 2018, 7, e33.	1.9	28

#	Article	IF	Citations
19	Interaction between diet and gastrointestinal endocrine cells. Biomedical Reports, 2016, 4, 651-656.	2.0	26
20	Longâ€term effects of fecal microbiota transplantation (FMT) in patients with irritable bowel syndrome. Neurogastroenterology and Motility, 2022, 34, e14200.	3.0	25
21	The possible role of gastrointestinal endocrine cells in the pathophysiology of irritable bowel syndrome. Expert Review of Gastroenterology and Hepatology, 2017, 11, 139-148.	3.0	24
22	Reduction in duodenal endocrine cells in irritable bowel syndrome is associated with stem cell abnormalities. World Journal of Gastroenterology, 2015, 21, 9577.	3.3	24
23	Responses to faecal microbiota transplantation in female and male patients with irritable bowel syndrome. World Journal of Gastroenterology, 2021, 27, 2219-2237.	3.3	22
24	Pathophysiology of idiopathic gastroparesis and implications for therapy. Scandinavian Journal of Gastroenterology, 2019, 54, 8-17.	1.5	19
25	Densities of rectal peptide YY and somatostatin cells as biomarkers for the diagnosis of irritable bowel syndrome. Peptides, 2015, 67, 12-19.	2.4	18
26	Stomach antral endocrine cells in patients with irritable bowel syndrome. International Journal of Molecular Medicine, 2014, 34, 967-974.	4.0	17
27	Changes in enteroendocrine and immune cells following colitis induction by TNBS in rats. Molecular Medicine Reports, 2016, 14, 4967-4974.	2.4	17
28	Chromogranin A cell density in the large intestine of Asian and European patients with irritable bowel syndrome. Scandinavian Journal of Gastroenterology, 2017, 52, 691-697.	1.5	16
29	Gastric Emptying of Low- and High-Caloric Liquid Meals Measured Using Ultrasonography in Healthy Volunteers. Ultrasound International Open, 2019, 05, E27-E33.	0.6	16
30	Overlapping of irritable bowel syndrome with erosive esophagitis and the performance of Rome criteria in diagnosing IBS in a clinical setting. Molecular Medicine Reports, 2019, 20, 787-794.	2.4	14
31	Abnormalities in endocrine and immune cells are correlated in dextran-sulfate-sodium-induced colitis in rats. Molecular Medicine Reports, 2017, 15, 12-20.	2.4	11
32	Study protocol of the Bergen brain-gut-microbiota-axis study. Medicine (United States), 2020, 99, e21950.	1.0	11
33	Enteroendocrine, Musashi 1 and neurogenin 3 cells in the large intestine of Thai and Norwegian patients with irritable bowel syndrome. Scandinavian Journal of Gastroenterology, 2017, 52, 1331-1339.	1.5	10
34	Effects of a Cod Protein Hydrolysate Supplement on Symptoms, Gut Integrity Markers and Fecal Fermentation in Patients with Irritable Bowel Syndrome. Nutrients, 2019, 11, 1635.	4.1	10
35	Supplementation with Low Doses of a Cod Protein Hydrolysate on Glucose Regulation and Lipid Metabolism in Adults with Metabolic Syndrome: A Randomized, Double-Blind Study. Nutrients, 2020, 12, 1991.	4.1	9
36	Abnormal differentiation of stem cells into enteroendocrine cells in rats with DSS-induced colitis. Molecular Medicine Reports, 2017, 15, 2106-2112.	2.4	8

#	Article	IF	Citations
37	Ultrasound imaging for assessing functions of the GI tract. Physiological Measurement, 2021, 42, 024002.	2.1	8
38	Do patients with functional chest pain have neuroplastic reorganization of the pain matrix? A diffusion tensor imaging study. Scandinavian Journal of Pain, 2014, 5, 85-90.	1.3	7
39	Irritable bowel syndrome patients who are not likely to respond to fecal microbiota transplantation. Neurogastroenterology and Motility, 2022, , e14353.	3.0	7
40	The fecal microbiota transplantation response differs between patients with severe and moderate irritable bowel symptoms. Scandinavian Journal of Gastroenterology, 2022, 57, 1036-1045.	1.5	7
41	Acute effect of a cod protein hydrolysate on postprandial acylated ghrelin concentration and sensations associated with appetite in healthy subjects: a double-blind crossover trial. Food and Nutrition Research, 2019, 63, .	2.6	6
42	Peroral endoscopic pyloromyotomy for primary pyloric stenosis. Endoscopy, 2015, 47, E637-E638.	1.8	5
43	The Effect of Supplementation with Low Doses of a Cod Protein Hydrolysate on Satiety Hormones and Inflammatory Biomarkers in Adults with Metabolic Syndrome: A Randomized, Double-Blind Study. Nutrients, 2020, 12, 3421.	4.1	4
44	Gastroparesis Symptoms Associated with Intestinal Hypomotility: An Explorative Study Using Wireless Motility Capsule. Clinical and Experimental Gastroenterology, 2021, Volume 14, 133-144.	2.3	3
45	ULTRASOUND IN PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE. Advanced Series in Biomechanics, 2005, , 461-490.	0.1	1
46	Density of Musashiâ€˜1â€˜positive stem cells in the stomach of patients with irritable bowel syndrome. Molecular Medicine Reports, 2020, 22, 3135-3140.	2.4	1
47	Letter: faecal microbiota transplantation for irritable bowel syndromeâ€”which improvements are required?. Alimentary Pharmacology and Therapeutics, 2020, 52, 1752-1753.	3.7	1